Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-1965 in Advanced Solid Tumors
NCT06234098Phase 2Recruiting
- Sponsor
- Alyssum Therapeutics
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AT-1965 in solid tumor and triple-negative breast cancer (TNBC), sponsored by Alyssum Therapeutics. Primary endpoints: Dose Limiting Toxicity at 28 days, Objective Response Rate at 9 months and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
AT-1965
03
Conditions
solid tumortriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06234098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234098.